Giovanni Battista Bonfioli, Daniela Tomasoni, Giuseppe Vergaro, Vincenzo Castiglione, Marianna Adamo, Iacopo Fabiani, Victor Loghin, Carlo Mario Lombardi, Alessio Nicolai, Marco Metra, Michele Emdin, Alberto Aimo
{"title":"在疑似心脏淀粉样变性患者中，梅奥 ATTR-CM 评分与其他诊断评分和心脏生物标志物的比较","authors":"Giovanni Battista Bonfioli, Daniela Tomasoni, Giuseppe Vergaro, Vincenzo Castiglione, Marianna Adamo, Iacopo Fabiani, Victor Loghin, Carlo Mario Lombardi, Alessio Nicolai, Marco Metra, Michele Emdin, Alberto Aimo","doi":"10.1002/ejhf.3455","DOIUrl":null,"url":null,"abstract":"Several scores were developed to help the diagnosis of cardiac amyloidosis (CA). The most recent one, being the Mayo transthyretin amyloidosis cardiomyopathy (ATTR-CM) score, was not externally validated. We compared the diagnostic performance of the ATTR-CM score with previous tools (increased wall thickness [IWT] score, AMYLoidosis Index [AMYLI] score, and cardiac biomarkers) in a cohort of patients evaluated for a suspicion of CA.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"383 1","pages":""},"PeriodicalIF":16.9000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis\",\"authors\":\"Giovanni Battista Bonfioli, Daniela Tomasoni, Giuseppe Vergaro, Vincenzo Castiglione, Marianna Adamo, Iacopo Fabiani, Victor Loghin, Carlo Mario Lombardi, Alessio Nicolai, Marco Metra, Michele Emdin, Alberto Aimo\",\"doi\":\"10.1002/ejhf.3455\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Several scores were developed to help the diagnosis of cardiac amyloidosis (CA). The most recent one, being the Mayo transthyretin amyloidosis cardiomyopathy (ATTR-CM) score, was not externally validated. We compared the diagnostic performance of the ATTR-CM score with previous tools (increased wall thickness [IWT] score, AMYLoidosis Index [AMYLI] score, and cardiac biomarkers) in a cohort of patients evaluated for a suspicion of CA.\",\"PeriodicalId\":164,\"journal\":{\"name\":\"European Journal of Heart Failure\",\"volume\":\"383 1\",\"pages\":\"\"},\"PeriodicalIF\":16.9000,\"publicationDate\":\"2024-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Heart Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ejhf.3455\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ejhf.3455","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
为帮助诊断心脏淀粉样变性（CA），已开发出多种评分方法。最新的梅奥经淀粉样蛋白淀粉样变性心肌病（ATTR-CM）评分未经外部验证。我们在一组因怀疑患有 CA 而接受评估的患者中比较了 ATTR-CM 评分与以前的工具（室壁厚度增加 [IWT] 评分、AMYLoidosis 指数 [AMYLI] 评分和心脏生物标志物）的诊断性能。
The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis
Several scores were developed to help the diagnosis of cardiac amyloidosis (CA). The most recent one, being the Mayo transthyretin amyloidosis cardiomyopathy (ATTR-CM) score, was not externally validated. We compared the diagnostic performance of the ATTR-CM score with previous tools (increased wall thickness [IWT] score, AMYLoidosis Index [AMYLI] score, and cardiac biomarkers) in a cohort of patients evaluated for a suspicion of CA.
期刊介绍：
European Journal of Heart Failure is an international journal dedicated to advancing knowledge in the field of heart failure management. The journal publishes reviews and editorials aimed at improving understanding, prevention, investigation, and treatment of heart failure. It covers various disciplines such as molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, clinical sciences, social sciences, and population sciences. The journal welcomes submissions of manuscripts on basic, clinical, and population sciences, as well as original contributions on nursing, care of the elderly, primary care, health economics, and other related specialist fields. It is published monthly and has a readership that includes cardiologists, emergency room physicians, intensivists, internists, general physicians, cardiac nurses, diabetologists, epidemiologists, basic scientists focusing on cardiovascular research, and those working in rehabilitation. The journal is abstracted and indexed in various databases such as Academic Search, Embase, MEDLINE/PubMed, and Science Citation Index.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
